Lexeo Therapeutics Inc [LXEO] stock is trading at $5.2, up 0.19%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The LXEO shares have gain 5.69% over the last week, with a monthly amount glided 17.12%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Lexeo Therapeutics Inc [NASDAQ: LXEO] stock has seen the most recent analyst activity on July 31, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $20. Previously, Robert W. Baird started tracking the stock with Outperform rating on June 13, 2024, and set its price target to $28. On June 06, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $22 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $20 on November 28, 2023. RBC Capital Mkts initiated its recommendation with a Outperform and recommended $22 as its price target on November 28, 2023. Leerink Partners started tracking with a Outperform rating for this stock on November 28, 2023, and assigned it a price target of $19. In a note dated November 28, 2023, JP Morgan initiated an Overweight rating and provided a target price of $20 on this stock.
Lexeo Therapeutics Inc [LXEO] stock has fluctuated between $1.45 and $11.72 over the past year. Currently, Wall Street analysts expect the stock to reach $28 within the next 12 months. Lexeo Therapeutics Inc [NASDAQ: LXEO] shares were valued at $5.2 at the most recent close of the market. An investor can expect a potential return of 438.46% based on the average LXEO price forecast.
Analyzing the LXEO fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -63.49%, Pretax Profit Margin comes in at -58.73%, and Net Profit Margin reading is -58.73%. To continue investigating profitability, this company’s Return on Assets is posted at -0.65, Equity is -0.95 and Total Capital is -0.85. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.08 points at the first support level, and at 4.96 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.36, and for the 2nd resistance point, it is at 5.52.
Ratios To Look Out For
For context, Lexeo Therapeutics Inc’s Current Ratio is 4.43. In addition, the Quick Ratio stands at 4.43 and the Cash Ratio stands at 1.12.
Transactions by insiders
Recent insider trading involved Otero Jose Manuel, Chief Technical Officer, that happened on Aug 18 ’25 when 2848.0 shares were sold. Chief Legal Officer, Robertson Jenny completed a deal on Aug 18 ’25 to sell 542.0 shares. Meanwhile, Chief Medical Officer Adler Eric sold 608.0 shares on Aug 18 ’25.
